Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 6NIH 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 48Cyclophosphamide 41Etoposide 34fludarabine phosphate 26Filgrastim 26Peripheral Blood Stem Cell Transplantation 25Radiotherapy 24Daunorubicin 24Vincristine 20Methotrexate 20Busulfan 18Mitoxantrone 15Idarubicin 15Doxorubicin 13Dexamethasone 13Rituximab 12Asparaginase 12Prednisone 11Mercaptopurine 11Cyclosporine 11Thioguanine 9Leucovorin 9Ifosfamide 9Antilymphocyte Serum 9laromustine 8Prednisolone 8fludarabine 7Methylprednisolone 7Interferon-alpha 7aldesleukin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Leukemia × Homoharringtonine × Clear all
NCT00030355 2013-03-22

Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

NCT00002574 2013-02-05

Homoharringtonine and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡